Prognostic Factors and Real-World Outcomes in Adolescents and Young Adults (AYA) With Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL) Treated With the AYA-15 Protocol: A Retrospective Cohort Study From a Tertiary Care Referral Center in the Middle East
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2025.07.006 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Amr Hanbali und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of hematology and cellular therapy, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia. Electronic address: ahanbali@…. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Adolescents and young adults (AYA) with Philadelphia-negative acute lymphoblastic leukemia (ALL) represent a distinct population with variable outcomes. This study assessed the real-world efficacy and safety of the AYA-15 protocol in this group. PATIENTS AND METHODS: A retrospective cohort of 149 AYA patients (median age: 18 years) treated with the AYA-15 protocol at a tertiary care center in the middle east was analyzed. Baseline characteristics, measurable residual disease (MRD) kinetics, toxicity profiles, and survival outcomes were examined. Multivariate Cox regression was performed to identify adverse prognostic factors. RESULTS: Among the 149 patients, 74% had B-cell ALL and 10% had central nervous system (CNS) involvement. Day 28 MRD negativity was achieved in 76% of patients, increasing to 88% post-consolidation. The 5-year overall survival (OS), disease-free survival (DFS), and event-free survival (EFS) rates were 79%, 68%, and 59%, respectively. The most common grade ≥3 toxicities included febrile neutropenia, infections, hepatotoxicity, and hypersensitivity reactions to PEG-asparaginase. Multivariable analysis identified CNS involvement, post-consolidation MRD positivity, and elevated BMI as independent predictors of inferior outcomes. CONCLUSION: The AYA-15 protocol demonstrated favorable survival and MRD response rates in a real-world cohort of Philadelphia-negative AYA ALL patients. Certain baseline and treatment-related factors were associated with poorer outcomes, highlighting the importance of individualized risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of hematology and cellular therapy, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia. Electronic address: ahanbali@kfshrc.edu.sa.
- Department of hematology and cellular therapy, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
- College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
- Department of hematology and cellular therapy, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia; Department of Medicine, Hematology unit, Zagazig University, Egypt.
Zitieren
APA
Hanbali, A., Saad, A., Ahmed, S. O., Alfayez, M., Madien, H., Alfaqawi, S., Aleid, M., Hamad, A., Desai, S., Alsarami, L., Alahmari, A., Alotaibi, A., Alkhaldi, H., Alfraih, F., Alhayli, S., Alshaibani, A., Albabtain, A., Alamer, A., Alotaibi, S., …, & Kotb, A. (2025). Prognostic Factors and Real-World Outcomes in Adolescents and Young Adults (AYA) With Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL) Treated With the AYA-15 Protocol: A Retrospective Cohort Study From a Tertiary Care Referral Center in the Middle East. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.07.006
Vancouver
Hanbali A, Saad A, Ahmed SO, Alfayez M, Madien H, Alfaqawi S, et al. Prognostic Factors and Real-World Outcomes in Adolescents and Young Adults (AYA) With Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL) Treated With the AYA-15 Protocol: A Retrospective Cohort Study From a Tertiary Care Referral Center in the Middle East. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.07.006
BibTeX
@article{Hanbali2025,
author = {Hanbali, Amr and Saad, Ayman and Ahmed, Syed Osman and Alfayez, Mansour and Madien, Heba and Alfaqawi, Samar and Aleid, Manar and Hamad, Alaa and Desai, Sameer and Alsarami, Leena and Alahmari, Ali and Alotaibi, Ahmad and Alkhaldi, Hanan and Alfraih, Feras and Alhayli, Saud and Alshaibani, Alfadel and Albabtain, Abdulwahab and Alamer, Abdullah and Alotaibi, Shaykhah and Shaheen, Marwan and Albanyan, Omar and Rasheed, Walid and Alsharif, Fahad and Chaudhri, Naeem and Almohareb, Fahad and Alzahrani, Hazzaa and Fakih, Riad El and Aljurf, Mahmoud and Kotb, Ahmed},
title = {Prognostic Factors and Real-World Outcomes in Adolescents and Young Adults (AYA) With Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL) Treated With the AYA-15 Protocol: A Retrospective Cohort Study From a Tertiary Care Referral Center in the Middle East},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2025.07.006}
}
EUVIMED